Wide Ranks

IXHL

Incannex Healthcare Inc.

1.82

Top Statistics
Market Cap 32 M Forward PE -0.9286 Revenue Growth 0.00 %
Current Ratio 2.88 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.61 Enterprise / Revenue 2483.39 Price To Sales Trailing12 Months 2675.82
Profitability
Profit Margins 0.00 % Operating Margins -53833.33 %
Balance Sheet
Total Cash 5 M Total Cash Per Share 0.3320 Total Debt 373000
Total Debt To Equity 3.33 Current Ratio 2.88 Book Value Per Share 0.6360
All Measures
Short Ratio 176.00 % Message Board Id finmb_325166139 Shares Short Prior Month 96072
Return On Equity -1.15 City Sydney Uuid 0fdfdd7c-e654-3cf0-aeac-51571750cdab
Previous Close 1.85 First Trade Date Epoch Utc 1 B Book Value 0.6360
Beta 2.21 Total Debt 373000 Volume 6102
Price To Book 2.86 Fifty Two Week Low 1.50 Total Cash Per Share 0.3320
Total Revenue 12000 Shares Short Previous Month Date 1 B Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -53833.33 % Net Income To Common -18459000
Short Percent Of Float 0.0037 Implied Shares Outstanding 17 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 33860 Average Volume10days 33860
Total Cash 5 M Next Fiscal Year End 1 B Revenue Per Share 0.0010
Held Percent Insiders 0.2586 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 1.85 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.10 Open 1.90
Free Cashflow -9322375 State NSW Dividend Yield 0.00 %
Return On Assets -0.5696 Time Zone Short Name EST Trailing Eps -1.36
Day Low 1.80 Address1 8 Century Circuit Shares Outstanding 17 M
Price Hint 4 Target High Price 0.0000 Website https://www.incannex.com
52 Week Change -0.7722 Average Volume 27309 Forward Eps -1.96
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 282.40 %
Is_sp_500 False Regular Market Day High 1.90 Profit Margins 0.00 %
Debt To Equity 3.33 Fifty Two Week High 12.68 Day High 1.90
Shares Short 49197 Regular Market Open 1.90 Industry Key drug-manufacturers-specialty-generic
Earnings Growth 0.00 % Enterprise To Revenue 2483.39 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0028 Operating Cashflow -15845000 Currency USD
Time Zone Full Name America/New_York Market Cap 32 M Is_nasdaq_100 False
Zip 2153 Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic
Long Name Incannex Healthcare Inc. Regular Market Day Low 1.80 Held Percent Institutions 0.0413
Current Price 1.82 Address2 Suite 105 Norwest Enterprise To Ebitda -1.61
Financial Currency USD Current Ratio 2.88 Gross Margins 100.00 %
Industry Disp Drug Manufacturers - Specialty & Generic Country Australia Float Shares 13 M
Two Hundred Day Average 2.65 Enterprise Value 29 M Price To Sales Trailing12 Months 2675.82
Forward PE -0.9286 Regular Market Volume 6102 Ebitda -18504000
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia.

The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.

It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease.

Incannex Healthcare Inc. is headquartered in Sydney, Australia.